{"id":"candesartan-plus-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Dizziness"},{"rate":"3-8","effect":"Fatigue"},{"rate":"1-3","effect":"Hyperkalemia (elevated potassium)"},{"rate":"2-5","effect":"Hypokalemia (low potassium)"},{"rate":"2-4","effect":"Hyperuricemia (elevated uric acid)"},{"rate":"3-7","effect":"Headache"},{"rate":"1-2","effect":"Cough"},{"rate":"2-5","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL1016","moleculeType":"Small molecule","molecularWeight":"440.46"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Candesartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels and the heart, causing vasodilation and reduced blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urine output and reducing blood volume. The combination provides complementary antihypertensive effects through different mechanisms.","oneSentence":"Candesartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume and sodium reabsorption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:02.372Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (high blood pressure)"},{"name":"Reduction of cardiovascular events in hypertensive patients"}]},"trialDetails":[{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":"Hypertension","enrollment":702},{"nctId":"NCT02774460","phase":"PHASE4","title":"The Precision Hypertension Care Study","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2017-02-20","conditions":"Hypertension","enrollment":280},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT04521023","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-09-20","conditions":"Hypertension","enrollment":132},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT02094924","phase":"PHASE1","title":"A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-17","conditions":"Hypertension","enrollment":16},{"nctId":"NCT02521246","phase":"PHASE3","title":"Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"2016-11","conditions":"Essential Arterial Hypertension","enrollment":""},{"nctId":"NCT02521233","phase":"PHASE3","title":"Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"2016-11","conditions":"Essential Arterial Hypertension","enrollment":""},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00360178","phase":"PHASE3","title":"Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-07","conditions":"Hypertension","enrollment":198},{"nctId":"NCT00232882","phase":"PHASE4","title":"Pharmacodynamic Influences of Candesartan, Atenolol, Hydrochlorothiazide and Drug Combinations in Hypertensive Patients.","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2003-12","conditions":"Hypertension","enrollment":86},{"nctId":"NCT00005520","phase":"","title":"Genetic Epidemiology of Responses to Antihypertensives","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"1997-02","conditions":"Cardiovascular Diseases, Heart Diseases, Hypertension","enrollment":1200},{"nctId":"NCT00775814","phase":"PHASE4","title":"Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-10","conditions":"Obesity, Hypertension","enrollment":188},{"nctId":"NCT01198496","phase":"PHASE4","title":"Recurrent Stroke Prevention Clinical Outcome Study","status":"UNKNOWN","sponsor":"Biomedis International Ltd.","startDate":"2010-10","conditions":"Hypertension, Stroke, Blood Pressure","enrollment":5000},{"nctId":"NCT00867490","phase":"PHASE3","title":"Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-03","conditions":"Hypertension","enrollment":186},{"nctId":"NCT00670787","phase":"PHASE3","title":"Combination Pill of Losartan Potassium and Hydrochlorothiazide for Improvement of Medication Compliance Trial","status":"COMPLETED","sponsor":"Kyushu University","startDate":"2008-06","conditions":"Hypertension","enrollment":207},{"nctId":"NCT00434967","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Hypertension","enrollment":2207},{"nctId":"NCT00526279","phase":"","title":"COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-06","conditions":"Hypertension","enrollment":9000},{"nctId":"NCT01012479","phase":"PHASE4","title":"Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-10","conditions":"Hypertension","enrollment":107},{"nctId":"NCT00621153","phase":"PHASE4","title":"Candesartan Effect in Second Stage Arterial Hypertension","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-02","conditions":"Stage II Hypertension","enrollment":214},{"nctId":"NCT00383929","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Hypertension","enrollment":1979},{"nctId":"NCT00607633","phase":"","title":"Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Essential Hypertension, Left Ventricular Hypertrophy","enrollment":686},{"nctId":"NCT00608153","phase":"","title":"Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Essential Hypertension","enrollment":1773}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Candesartan plus Hydrochlorothiazide","genericName":"Candesartan plus Hydrochlorothiazide","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Candesartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume and sodium reabsorption. Used for Hypertension (high blood pressure), Reduction of cardiovascular events in hypertensive patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}